Obalon Therapeutics Inc., of San Diego, said it entered definitive agreements with investors for the purchase and sale of 5 million shares at 60 cents each in a registered direct offering for gross proceeds of approximately $3 million before deducting fees and other estimated offering expenses. It intends to use the net proceeds for general corporate purposes.